Abstract
Background: Hemorrhagic transformation (HT) is a common and natural complication after acute ischemic stroke. The only FDA-approved treatment so far for acute ischemic stroke is rapid reperfusion with recombinant tissue plasminogen activator (rtPA). Although it has been shown to exaggerate the risk and severity of HT and to be associated with increased morbidity and mortality.
Objective: The aim of this review is to discuss the multifactorial pathophysiology of hemorrhagic transformation, promising interventional targets, and pharmacological treatment options. Results and Conclusion: Understanding HT is essential to restore cerebral blood flow to ischemic brain by reperfusion therapy without causing this complication and additional brain injury. Therefore methods for the prevention and treatment of HT are needed. Although experimental studies showed promising results, clinical translation remains unsatisfactory to date.Keywords: Cerebral ischemia, conversion, hemorrhagic transformation, prevention, stroke, treatment.
Graphical Abstract
Current Drug Targets
Title:Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Volume: 18 Issue: 12
Author(s): Wing Mann Ho, Cesar Reis, Onat Akyol, Gokce Yilmaz Akyol, Richard Applegate II, Gary Stier, Robert Martin and John H. Zhang*
Affiliation:
- Department of Neurosurgery, Loma Linda University Medical Center, 11234 Anderson Street, Room 2562B, Loma Linda, CA 92354,United States
Keywords: Cerebral ischemia, conversion, hemorrhagic transformation, prevention, stroke, treatment.
Abstract: Background: Hemorrhagic transformation (HT) is a common and natural complication after acute ischemic stroke. The only FDA-approved treatment so far for acute ischemic stroke is rapid reperfusion with recombinant tissue plasminogen activator (rtPA). Although it has been shown to exaggerate the risk and severity of HT and to be associated with increased morbidity and mortality.
Objective: The aim of this review is to discuss the multifactorial pathophysiology of hemorrhagic transformation, promising interventional targets, and pharmacological treatment options. Results and Conclusion: Understanding HT is essential to restore cerebral blood flow to ischemic brain by reperfusion therapy without causing this complication and additional brain injury. Therefore methods for the prevention and treatment of HT are needed. Although experimental studies showed promising results, clinical translation remains unsatisfactory to date.Export Options
About this article
Cite this article as:
Ho Mann Wing, Reis Cesar, Akyol Onat, Akyol Yilmaz Gokce, Applegate II Richard, Stier Gary, Martin Robert and Zhang H. John*, Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation, Current Drug Targets 2017; 18 (12) . https://dx.doi.org/10.2174/1389450117666160818115850
DOI https://dx.doi.org/10.2174/1389450117666160818115850 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors
Current Drug Delivery Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets DL-3-n-Butylphthalide, an Anti-Oxidant Agent, Prevents Neurological Deficits and Cerebral Injury Following Stroke per Functional Analysis, Magnetic Resonance Imaging and Histological Assessment
Current Neurovascular Research Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Antileukotriene Drugs: Clinical Application, Effectiveness and Safety
Current Medicinal Chemistry Neurobiological and Psychosocial Processes Associated with Depressive and Substance-Related Disorders in Adolescents
Current Drug Abuse Reviews Therapeutic Medical Hypothermia-A Multispecialty Approach
Recent Patents on Cardiovascular Drug Discovery Diabetes and Nutritional Screening in Post-Bariatric Patients
Current Diabetes Reviews Editorial (Thematic Issue: Effective and Promising Treatments for Neurological Disorders and Cancer)
Current Pharmaceutical Design Targeted Radiotherapy for Malignant Gliomas
Current Drug Discovery Technologies Drugs of Abuse and Oxidative Stress in the Brain: From Animal Models to Human Evidence
Mini-Reviews in Organic Chemistry Quantitative Machine Learning Analysis of Brain MRI Morphology throughout Aging
Current Aging Science Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design Concentration-Dependent Mechanisms of Adverse Drug Reactions in Epilepsy
Current Pharmaceutical Design Focus on the Role of Glutamate in the Pathology of the Peripheral Nervous System
CNS & Neurological Disorders - Drug Targets Clozapine Safety, 40 Years Later
Current Drug Safety Analytical Methods for Determination of ·NO and ·NO2 and their Applicability in Biological Studies
Current Pharmaceutical Analysis Synthesis, Antioxidant and Anti-inflammatoy Effects of Antioxidant Acid Amides with GABA and N-Acyl-pyrrolidin-2-ones
Current Chemical Biology Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Pharmacophore, QSAR, and Binding Mode Studies of Substrates of Human Cytochrome P450 2D6 (CYP2D6) Using Molecular Docking and Virtual Mutations and an Application to Chinese Herbal Medicine Screening
Current Pharmaceutical Biotechnology